ID   MP2K1_HUMAN             Reviewed;         393 AA.
AC   Q02750;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   02-NOV-2010, entry version 120.
DE   RecName: Full=Dual specificity mitogen-activated protein kinase kinase 1;
DE            Short=MAP kinase kinase 1;
DE            Short=MAPKK 1;
DE            EC=2.7.12.2;
DE   AltName: Full=ERK activator kinase 1;
DE   AltName: Full=MAPK/ERK kinase 1;
DE            Short=MEK 1;
GN   Name=MAP2K1; Synonyms=MEK1, PRKMK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=93100262; PubMed=1281467;
RA   Seger R., Seger D., Lozeman F.J., Ahn N.G., Graves L.M.,
RA   Campbell J.S., Ericsson L., Harrylock M., Jensen A.M., Krebs E.G.;
RT   "Human T-cell mitogen-activated protein kinase kinases are related to
RT   yeast signal transduction kinases.";
RL   J. Biol. Chem. 267:25628-25631(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=93266604; PubMed=8388392;
RA   Zheng C.-F., Guan K.-L.;
RT   "Cloning and characterization of two distinct human extracellular
RT   signal-regulated kinase activator kinases, MEK1 and MEK2.";
RL   J. Biol. Chem. 268:11435-11439(1993).
RN   [3]
RP   PHOSPHORYLATION AT SER-218 AND SER-222, AND MUTAGENESIS.
RX   MEDLINE=94178255; PubMed=8131746;
RA   Zheng C.-F., Guan K.-L.;
RT   "Activation of MEK family kinases requires phosphorylation of two
RT   conserved Ser/Thr residues.";
RL   EMBO J. 13:1123-1131(1994).
RN   [4]
RP   CLEAVAGE BY ANTHRAX LETHAL FACTOR, AND PROTEIN SEQUENCE OF 9-17.
RX   MEDLINE=98230732; PubMed=9563949; DOI=10.1126/science.280.5364.734;
RA   Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R.,
RA   Copeland T.D., Ahn N.G., Oskarsson M.K., Fukasawa K., Paull K.D.,
RA   Vande Woude G.F.;
RT   "Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal
RT   factor.";
RL   Science 280:734-737(1998).
RN   [5]
RP   CLEAVAGE BY ANTHRAX LETHAL FACTOR.
RX   MEDLINE=20558083; PubMed=11104681; DOI=10.1042/0264-6021:3520739;
RA   Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C.;
RT   "Susceptibility of mitogen-activated protein kinase kinase family
RT   members to proteolysis by anthrax lethal factor.";
RL   Biochem. J. 352:739-745(2000).
RN   [6]
RP   INTERACTION WITH YOPJ, AND ACETYLATION.
RX   PubMed=16728640; DOI=10.1126/science.1126867;
RA   Mukherjee S., Keitany G., Li Y., Wang Y., Ball H.L., Goldsmith E.J.,
RA   Orth K.;
RT   "Yersinia YopJ acetylates and inhibits kinase activation by blocking
RT   phosphorylation.";
RL   Science 312:1211-1214(2006).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-222, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-231; THR-286 AND
RP   THR-386, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-385, AND MASS
RP   SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [11]
RP   VARIANTS CFC SYNDROME SER-53 AND CYS-130.
RX   PubMed=16439621; DOI=10.1126/science.1124642;
RA   Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A.,
RA   Cruz M.S., McCormick F., Rauen K.A.;
RT   "Germline mutations in genes within the MAPK pathway cause cardio-
RT   facio-cutaneous syndrome.";
RL   Science 311:1287-1290(2006).
CC   -!- FUNCTION: Catalyzes the concomitant phosphorylation of a threonine
CC       and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP
CC       kinases. Activates ERK1 and ERK2 MAP kinases.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Activated by phosphorylation.
CC   -!- SUBUNIT: Interacts with MORG1. Interacts with ARRB2 (By
CC       similarity). Interacts with Yersinia yopJ.
CC   -!- INTERACTION:
CC       Q9NR09:BIRC6; NbExp=1; IntAct=EBI-492564, EBI-1765160;
CC       P04049:RAF1; NbExp=1; IntAct=EBI-492564, EBI-365996;
CC       Q96RU8:TRIB1; NbExp=1; IntAct=EBI-492564, EBI-492555;
CC       Q96RU7:TRIB3; NbExp=1; IntAct=EBI-492564, EBI-492476;
CC       Q86Y07:VRK2; NbExp=2; IntAct=EBI-492564, EBI-1207615;
CC   -!- PTM: Phosphorylation on Ser/Thr by MAP kinase kinase kinases (RAF
CC       or MEKK1) regulates positively the kinase activity.
CC   -!- PTM: Acetylation by Yersinia yopJ prevents phosphorylation and
CC       activation, thus blocking the MAPK signaling pathway.
CC   -!- DISEASE: Defects in MAP2K1 are a cause of cardiofaciocutaneous
CC       syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-
CC       cutaneous syndrome. CFC syndrome is characterized by a distinctive
CC       facial appearance, heart defects and mental retardation. Heart
CC       defects include pulmonic stenosis, atrial septal defects and
CC       hypertrophic cardiomyopathy. Some affected individuals present
CC       with ectodermal abnormalities such as sparse, friable hair,
CC       hyperkeratotic skin lesions and a generalized ichthyosis-like
CC       condition. Typical facial features are similar to Noonan syndrome.
CC       They include high forehead with bitemporal constriction,
CC       hypoplastic supraorbital ridges, downslanting palpebral fissures,
CC       a depressed nasal bridge, and posteriorly angulated ears with
CC       prominent helices. The inheritance of CFC syndrome is autosomal
CC       dominant.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/MAP2K1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L05624; AAA36318.1; -; mRNA.
DR   EMBL; L11284; -; NOT_ANNOTATED_CDS; mRNA.
DR   IPI; IPI00219604; -.
DR   PIR; A45100; A45100.
DR   RefSeq; NP_002746.1; -.
DR   UniGene; Hs.145442; -.
DR   PDB; 1S9J; X-ray; 2.40 A; A=62-392.
DR   PDB; 2P55; X-ray; 2.80 A; A=62-393.
DR   PDB; 3DV3; X-ray; 2.30 A; A=62-382.
DR   PDB; 3DY7; X-ray; 2.70 A; A=62-393.
DR   PDB; 3E8N; X-ray; 2.50 A; A=62-393.
DR   PDB; 3EQB; X-ray; 2.62 A; A=62-393.
DR   PDB; 3EQC; X-ray; 1.80 A; A=35-393.
DR   PDB; 3EQD; X-ray; 2.10 A; A=35-393.
DR   PDB; 3EQF; X-ray; 2.70 A; A=35-393.
DR   PDB; 3EQG; X-ray; 2.50 A; A=35-393.
DR   PDB; 3EQH; X-ray; 2.00 A; A=35-393.
DR   PDB; 3EQI; X-ray; 1.90 A; A=35-393.
DR   PDB; 3MBL; X-ray; 2.60 A; A=62-382.
DR   PDBsum; 1S9J; -.
DR   PDBsum; 2P55; -.
DR   PDBsum; 3DV3; -.
DR   PDBsum; 3DY7; -.
DR   PDBsum; 3E8N; -.
DR   PDBsum; 3EQB; -.
DR   PDBsum; 3EQC; -.
DR   PDBsum; 3EQD; -.
DR   PDBsum; 3EQF; -.
DR   PDBsum; 3EQG; -.
DR   PDBsum; 3EQH; -.
DR   PDBsum; 3EQI; -.
DR   PDBsum; 3MBL; -.
DR   ProteinModelPortal; Q02750; -.
DR   DIP; DIP-201N; -.
DR   IntAct; Q02750; 27.
DR   MINT; MINT-99632; -.
DR   STRING; Q02750; -.
DR   PhosphoSite; Q02750; -.
DR   PeptideAtlas; Q02750; -.
DR   PRIDE; Q02750; -.
DR   Ensembl; ENST00000307102; ENSP00000302486; ENSG00000169032.
DR   GeneID; 5604; -.
DR   KEGG; hsa:5604; -.
DR   UCSC; uc010bhq.1; human.
DR   CTD; 5604; -.
DR   GeneCards; GC15P066679; -.
DR   H-InvDB; HIX0038157; -.
DR   HGNC; HGNC:6840; MAP2K1.
DR   HPA; CAB003834; -.
DR   HPA; HPA026430; -.
DR   MIM; 115150; phenotype.
DR   MIM; 176872; gene.
DR   Orphanet; 1340; Cardiofaciocutaneous syndrome.
DR   PharmGKB; PA30584; -.
DR   eggNOG; prNOG13928; -.
DR   HOGENOM; HBG755340; -.
DR   HOVERGEN; HBG108518; -.
DR   InParanoid; Q02750; -.
DR   OMA; ELMFGCP; -.
DR   OrthoDB; EOG966Z66; -.
DR   PhylomeDB; Q02750; -.
DR   BRENDA; 2.7.12.2; 247.
DR   Pathway_Interaction_DB; bcr_5pathway; BCR signaling pathway.
DR   Pathway_Interaction_DB; anthraxpathway; Cellular roles of Anthrax toxin.
DR   Pathway_Interaction_DB; ceramidepathway; Ceramide signaling pathway.
DR   Pathway_Interaction_DB; pi3kcibpathway; Class IB PI3K non-lipid kinase events.
DR   Pathway_Interaction_DB; cd8tcrdownstreampathway; Downstream signaling in naive CD8+ T cells.
DR   Pathway_Interaction_DB; endothelinpathway; Endothelins.
DR   Pathway_Interaction_DB; ephbfwdpathway; EPHB forward signaling.
DR   Pathway_Interaction_DB; fcer1pathway; Fc-epsilon receptor I signaling in mast cells.
DR   Pathway_Interaction_DB; foxm1pathway; FOXM1 transcription factor network.
DR   Pathway_Interaction_DB; hedgehog_glipathway; Hedgehog signaling events mediated by Gli proteins.
DR   Pathway_Interaction_DB; ifngpathway; IFN-gamma pathway.
DR   Pathway_Interaction_DB; il2_1pathway; IL2-mediated signaling events.
DR   Pathway_Interaction_DB; trkrpathway; Neurotrophic factor-mediated Trk receptor signaling.
DR   Pathway_Interaction_DB; tcrraspathway; Ras signaling in the CD4+ TCR pathway.
DR   Pathway_Interaction_DB; met_pathway; Signaling events activated by Hepatocyte Growth Factor Receptor (c-Met).
DR   Pathway_Interaction_DB; kitpathway; Signaling events mediated by Stem cell factor receptor (c-Kit).
DR   Pathway_Interaction_DB; mapktrkpathway; Trk receptor signaling mediated by the MAPK pathway.
DR   Reactome; REACT_11061; Signalling by NGF.
DR   Reactome; REACT_16888; Signaling by PDGF.
DR   Reactome; REACT_18266; Axon guidance.
DR   Reactome; REACT_498; Signaling by Insulin receptor.
DR   Reactome; REACT_6900; Signaling in Immune system.
DR   Reactome; REACT_9417; Signaling by EGFR.
DR   NextBio; 21776; -.
DR   PMAP-CutDB; Q02750; -.
DR   ArrayExpress; Q02750; -.
DR   Bgee; Q02750; -.
DR   CleanEx; HS_MAP2K1; -.
DR   Genevestigator; Q02750; -.
DR   GermOnline; ENSG00000169032; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004708; F:MAP kinase kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; EXP:Reactome.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0007050; P:cell cycle arrest; IMP:BHF-UCL.
DR   GO; GO:0006935; P:chemotaxis; TAS:ProtInc.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0007265; P:Ras protein signal transduction; EXP:Reactome.
DR   GO; GO:0010149; P:senescence; IMP:BHF-UCL.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Kinase;
KW   Nucleotide-binding; Phosphoprotein; Serine/threonine-protein kinase;
KW   Transferase; Tyrosine-protein kinase.
FT   INIT_MET      1      1       Removed (By similarity).
FT   CHAIN         2    393       Dual specificity mitogen-activated
FT                                protein kinase kinase 1.
FT                                /FTId=PRO_0000086365.
FT   DOMAIN       68    361       Protein kinase.
FT   NP_BIND      74     82       ATP (By similarity).
FT   COMPBIAS    262    307       Pro-rich.
FT   ACT_SITE    190    190       Proton acceptor (By similarity).
FT   BINDING      97     97       ATP.
FT   SITE          8      9       Cleavage; by anthrax lethal factor.
FT   MOD_RES     218    218       Phosphoserine; by RAF.
FT   MOD_RES     222    222       Phosphoserine; by RAF.
FT   MOD_RES     231    231       Phosphoserine.
FT   MOD_RES     286    286       Phosphothreonine.
FT   MOD_RES     385    385       Phosphoserine.
FT   MOD_RES     386    386       Phosphothreonine.
FT   VARIANT      53     53       F -> S (in CFC syndrome).
FT                                /FTId=VAR_035093.
FT   VARIANT     130    130       Y -> C (in CFC syndrome).
FT                                /FTId=VAR_035094.
FT   MUTAGEN      97     97       K->R: Inactivation.
FT   MUTAGEN     150    150       S->A: No loss of activity.
FT   MUTAGEN     212    212       S->A: No loss of activity.
FT   MUTAGEN     218    218       S->A: Inactivation.
FT   MUTAGEN     222    222       S->A: Inactivation.
FT   HELIX        65     67
FT   STRAND       68     75
FT   STRAND       82     87
FT   TURN         88     91
FT   STRAND       92    100
FT   HELIX       107    114
FT   HELIX       115    120
FT   STRAND      129    134
FT   STRAND      136    144
FT   HELIX       151    158
FT   HELIX       163    184
FT   HELIX       193    195
FT   STRAND      196    198
FT   STRAND      204    206
FT   HELIX       213    218
FT   HELIX       232    236
FT   HELIX       244    258
FT   HELIX       270    274
FT   HELIX       310    318
FT   HELIX       332    341
FT   TURN        346    348
FT   HELIX       352    356
FT   HELIX       359    366
FT   HELIX       371    379
SQ   SEQUENCE   393 AA;  43439 MW;  0344118FFC842D51 CRC64;
     MPKKKPTPIQ LNPAPDGSAV NGTSSAETNL EALQKKLEEL ELDEQQRKRL EAFLTQKQKV
     GELKDDDFEK ISELGAGNGG VVFKVSHKPS GLVMARKLIH LEIKPAIRNQ IIRELQVLHE
     CNSPYIVGFY GAFYSDGEIS ICMEHMDGGS LDQVLKKAGR IPEQILGKVS IAVIKGLTYL
     REKHKIMHRD VKPSNILVNS RGEIKLCDFG VSGQLIDSMA NSFVGTRSYM SPERLQGTHY
     SVQSDIWSMG LSLVEMAVGR YPIPPPDAKE LELMFGCQVE GDAAETPPRP RTPGRPLSSY
     GMDSRPPMAI FELLDYIVNE PPPKLPSGVF SLEFQDFVNK CLIKNPAERA DLKQLMVHAF
     IKRSDAEEVD FAGWLCSTIG LNQPSTPTHA AGV
//
